Valley Medical Pharmacy 
630 Main Street 
Brawley, CA 92227 
eRx ID#0585957 
1 (800) 322-0808 | Toll Free Fax: 1 (855) 322-0808 
Email: drugsdepot@yahoo.com 
Web: www.drugsdepot 
Timing: Monday to Friday | 9:00 AM to 5:45 PM 


Denavir 1% Cream 5 Gm By Prestium Pharma.

Image 0 of Denavir 1% Cream 5 Gm By Prestium Pharma.

Denavir 1% Cream 5 Gm By Prestium Pharma.

Call for Price

Denavir 1% Cream 5 Gm By Prestium Pharma. This Item Requires A Valid Order From A Physician Licensed in USA. Item Number.:RXB10124958/RXB4904496/RXA391226
Size : 5 GM
Selling UoM : EA
NDC: 40076-0624-05
UPC Barcode : 340076624053
Supplier: 0050002982 PRESTIUM PHARMA INC
Supplier Material : 062405
Generic Code : 027545 PENCICLOVIR TOPICAL CREAM (G) 1 %
Fine Line Class : 850085008510 All Rx Products
Product Category : RX Pharmaceuticals
Product Type : BRX Branded RX

Have a question?

  Call for Price

Product Description.:

Denavir contains penciclovir, an antiviral agent active against herpes viruses. Denavir is available for topical administration as a 1% white cream. Each gram of Denavir contains 10 mg of penciclovir and the following inactive ingredients: cetomacrogol 1000 BP, cetostearyl alcohol, mineral oil, propylene glycol, purified water and white petrolatum.

Penciclovir is a white to pale yellow solid. At 20?C it has a solubility of 0.2 mg/mL in methanol, 1.3 mg/mL in propylene glycol, and 1.7 mg/mL in water. In aqueous buffer (pH 2) the solubility is 10.0 mg/mL. Penciclovir is not hygroscopic. Its partition coefficient in n-octanol/water at pH 7.5 is 0.024 (logP= -1.62).

INDICATIONS

Denavir (penciclovir cream) is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older.
DOSAGE AND ADMINISTRATION

Denavir should be applied every 2 hours during waking hours for a period of 4 days. Treatment should be started as early as possible (i.e., during the prodrome or when lesions appear).

Side Effects & Drug Interactions
font size
A
A
A

Denavir?
(penciclovir) Cream 1%

For Dermatologic Use Only
DRUG DESCRIPTION

Denavir contains penciclovir, an antiviral agent active against herpes viruses. Denavir is available for topical administration as a 1% white cream. Each gram of Denavir contains 10 mg of penciclovir and the following inactive ingredients: cetomacrogol 1000 BP, cetostearyl alcohol, mineral oil, propylene glycol, purified water and white petrolatum.

Chemically, penciclovir is known as 9-[4-hydroxy-3-(hydroxymethyl) butyl]guanine. Its molecular formula is C10H15N5O3 its molecular weight is 253.26. It is a synthetic acyclic guanine derivative and has the following structure:

Denavir? (penciclovir) Structural Formula Illustration

Penciclovir

Penciclovir is a white to pale yellow solid. At 20?C it has a solubility of 0.2 mg/mL in methanol, 1.3 mg/mL in propylene glycol, and 1.7 mg/mL in water. In aqueous buffer (pH 2) the solubility is 10.0 mg/mL. Penciclovir is not hygroscopic. Its partition coefficient in n-octanol/water at pH 7.5 is 0.024 (logP= -1.62).

Last updated on RxList: 12/9/2008
INDICATIONS

Denavir (penciclovir cream) is indicated for the treatment of recurrent herpes labialis (cold sores) in adults and children 12 years of age and older.
DOSAGE AND ADMINISTRATION

Denavir should be applied every 2 hours during waking hours for a period of 4 days. Treatment should be started as early as possible (i.e., during the prodrome or when lesions appear).
HOW SUPPLIED

Denavir is supplied in a 1.5 gram tube containing 10 mg of penciclovir per gram. NDC 0067-6024-15

Store at controlled room temperature, 20?-25? C (68?-77?F) [see USP]

QUESTIONS? call 1-800-452-0051 24 hours a day, 7 days a week.

Manufactured by Novartis Pharma GmbH, Wehr, Germany for Novartis Consumer Health, Inc. Parsippany, NJ 07054-0622. FDA Rev date: 10/10/2003

Last updated on RxList: 12/9/2008
SIDE EFFECTS

In two double-blind, placebo-controlled trials, 1516 patients were treated with Denavir (penciclovir cream) and 1541 with placebo. The most frequently reported adverse event was headache, which occurred in 5.3% of the patients treated with Denavir and 5.8% of the placebo-treated patients.